Introduction {#S0001}
============

Cervical cancer is the second most common cancer among women worldwide;[@CIT0001] however, among all cancers, cervical cancer is the easiest to prevent by screening.[@CIT0002] Thus, it is particularly important to optimize screening programs to reduce the burden of cervical cancer. Currently, guidelines tend to recommend "three steps" for the diagnosis of cervical lesions: liquid cytology and high-risk human papillomavirus (HR-HPV), colposcopy (an observation method that can identify potential premalignant and malignant lesions) and histology.[@CIT0003] Women may need further follow-up and/or treatment based on the severity of the lesion when atypical transformation is detected by cytology. Women with cytology-proven severe lesions should be referred and further examined according to the guidelines, which involve colposcopy and biopsy obtained under colposcopy.[@CIT0004],[@CIT0005] However, the management strategy for women with atypical squamous cells of undetermined significance (ASCUS) remains controversial.[@CIT0006] ASCUS is not a specific diagnosis of progression or disease; rather, this indistinct diagnosis encompasses normal, low-grade squamous intraepithelial lesions (LSIL), high-squamous intraepithelial lesions (HSIL) and invasive cancer.[@CIT0007] The consensus guidelines proposed in 2006 recommend three alternative treatments for women with ASCUS who have abnormal cell smears: repeat the cervical smear twice at 6-month intervals, repeat HR-HPV DNA tests and perform colposcopy.[@CIT0008] All of these options are safe and effective, depending on the situation and available resources.

Although most cases of ASCUS resolve with no apparent clinical disease, some (15--20%) are confirmed by histology to progress to cervical epithelial neoplasia (CIN) during follow-up.[@CIT0009] Previous research has indicated that the risk of CIN3 or worse (CIN3+) among women with ASCUS is significantly higher than that among women without ASCUS.[@CIT0010] Therefore, an accurate category for these patients is needed to determine who needs subsequent management.

The etiologic role of persistent infection with HR-HPV, which may contribute to the development of cervical cancer and its precursor, is well documented.[@CIT0011],[@CIT0012] Over the past 10 years, the assessment of HR-HPV genotype has been adopted to guide treatment for women with ASCUS, and colposcopy is recommended for all HR-HPV-positive cases.[@CIT0013] However, this management strategy may be overtreatment[@CIT0013] because of the different carcinogenicities of the different HPV genotypes, as the role of HPV in the evolution of CIN and invasive cancer varies by HPV genotype. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 are categorized as carcinogenic, and HPV66 is likely to be carcinogenic.[@CIT0014] Infection with HPV16 and HPV18 was found in 71% of cervical cancer cases.[@CIT0015] A previous study[@CIT0016] indicated that among HPV-infected cases with initial normal cytology, the incidence of CIN2 or worse (CIN2+) at 13.4 years of follow-up was as follows: 28.5% with HPV16 alone; 15.4% with HPV18 alone; 19.1% with type 33, 18.2% with type 35, 16.7% with type 58, 15.7% with type 31, 8.6% with type 51, 8.5% with type 45, 4.7% with type 52, 3.6% with type 39, and 2.8% with type 56. These data show the necessity of selecting appropriate HR-HPV genotypes for triaging ASCUS patients.

The ideal triage strategy for ASCUS patients is to maximize sensitivity and specificity, thereby reducing the rate of misdiagnosis and unnecessary colposcopy. Thus, our research was conducted to assess the performance of different HPV genotypes in triaging ASCUS patients in a Chinese population and offers new parameters to design the optimal strategy for ASCUS patient triage.

Patients and Methods {#S0002}
====================

Study Design and Participants {#S0002-S2001}
-----------------------------

A cervical cancer screening group of 36,679 women was set up from August 2015 to December 2019 in Fujian Province. All participants underwent cervical cytology and HPV genotyping assessments. Women who met the following criteria were enrolled in the study: age 21 years or older; history of sexual activity; not currently pregnant; no history of hysterectomy, cervical surgery, or cervical cancer treatment; and provided signed informed consent. The Ethical Committees of the Longyan First Hospital Affiliated to Fujian Medical University granted approval for this study (Approval number: 2019-020). The study was conducted in accordance with the Declaration of Helsinki. All participants in this study provided written informed consent.

Screening Protocols {#S0002-S2002}
-------------------

Prior to registration, a well-trained health care worker obtained informed consent and performed a confidential questionnaire-based interview with each included woman, evaluating her medical and surgical history of cervical lesions and cervical cancer, marital status, education level, smoking history, drinking history, and fertility history.

All qualified participants underwent gynecological examinations of the vulva, vagina and cervix. A doctor used a speculum to examine and collect cervical cells with plastic brushes. The cervical cells were collected in ThinPrep^®^ Pap Test PreservCyt^®^ Solution (Hologic Inc., Madison, WI, USA) and transported to the laboratory immediately, where they were stored at 4°C. The ThinPrep^®^ Cytologic Test (TCT) and HR-HPV genotyping test were performed on ThinPrep cervical cells.

If the liquid-based cytology test results showed ASCUS, colposcopy was performed within 10 weeks by an experienced gynecologist. A completely visible cervical transition area indicated satisfactory colposcopy; colposcopy exams that showed normal findings did not require a biopsy. In contrast, for women whose colposcopy evaluations revealed abnormalities, cervical biopsy was performed directly on the visible lesions. If colposcopy was unsatisfactory (the cervical transition area was not completely visible), endocervical curettage (ECC) was subsequently conducted ([Figure 1](#F0001){ref-type="fig"}). Women who were confirmed to be CIN2+ by biopsy histopathology were treated with conization/hysterectomy according to the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines,[@CIT0008] and histopathological examination was performed after conization/hysterectomy. The degree of cervical lesions was determined by the histopathology after conization/hysterectomy.Figure 1The flowchart of this study.**Abbreviations:** HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68; ASCUS, atypical squamous cells of undetermined significance; CIN1/2/3, cervical intraepithelial neoplasia grade 1/2/3; ECC, endocervical curettage; CIN2+, cervical intraepithelial neoplasia grade 2 or worse.

HR-HPV Genotyping Assay {#S0002-S2003}
-----------------------

We performed an HR-HPV genotyping assay with the HybriMax HPV GenoArray Test Kit (Chaozhou Hybribio Limited Corp., Chaozhou, China) according to the manufacturer's instructions. Previous research[@CIT0017],[@CIT0018] confirmed that the HybriMax HPV GenoArray Test Kit is an effective HR-HPV genotyping detection method, which has been approved by the China Food and Drug Administration (CFDA) for cervical cancer screening in China. The test is based on a DNA amplification, flow-through hybridization and gene-chip method, which can identify and distinguish 14 types of HR-HPV DNA in cervical exfoliated cells to detect each genotype. Specific primers and probes were designed for the HR-HPV L1 gene target sequence. Each experiment had positive and negative quality controls and blank controls. The reference gene b-globulin was measured simultaneously to determine false negatives due to insufficient sampling or manipulation errors.

Cytology and Histology {#S0002-S2004}
----------------------

The liquid-based cytology and Bethesda System (TBS) was used for the cytology test, and the CIN classification system was used for histology. For all histological results, the worst result was defined as the final result for each woman. If no biopsy was performed or if the histological result was negative, the woman was regarded as CIN-negative. Cell pathologists and histopathologists of Longyan First Hospital Affiliated to Fujian Medical University prepared and read the films. All liquid-based cytology and histopathology specimens were blinded and independently evaluated by two experienced cytopathologists and histopathologists. If the diagnoses differed, the sample was reviewed again, and a consensus diagnosis was obtained. A training session on colposcopy and histopathological diagnosis was convened to standardize the treatment protocols before the beginning of the study.

Statistical Analysis {#S0002-S2005}
--------------------

Analyses were carried out using SPSS version 24.0 (IBM Corporation, New York, USA). All women with ASCUS underwent colposcopy and/or ECC. The number of HR-HPV-positive ASCUS patients divided by the total number of ASCUS patients was regarded as the referral rate. When calculating the infection rate for a given HR-HPV genotype, we included all women with single and multiple infections who were positive for the genotype. The mean and standard deviation of the categorical variables and the values and percentages of the categorical variables were calculated. We calculated the odds ratio (OR) of age and different HPV types to evaluate the risk of CIN2+ among women with ASCUS. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) of the HR-HPV genotyping model for CIN2+ cervical lesions were also calculated and compared with the gold standard of the pathological diagnosis. All of these results were used to assess the accuracy and effectiveness of HR-HPV genotyping in the triage of women with ASCUS. The significance level was set at a P-value \<0.05.

Results {#S0003}
=======

Of the 36,679 women recruited, 34,532 were eligible and included in the study, 1675 (4.9%) had confirmed ASCUS by cytology, and 1454 (4.2%) who underwent colposcopy and/or biopsy were enrolled in this study. The characteristics of the ASCUS patients are shown in [Table 1](#T0001){ref-type="table"}. The mean age of the women at enrollment was 38.6±10.6 years (range 21--75 years). Approximately 92.2% had completed primary or higher education, 97.3% of those enrolled denied having a history of smoking, 80.9% denied having a history of drinking, 35.8% had more than 2 pregnancies, and 14.7% had more than 2 deliveries. ([Table 1](#T0001){ref-type="table"})Table 1Characteristics of the Study Population with Cytology-Proven ASCUS (N=1454)CharacteristicsNo. of Women (N=1454)Mean (x±s) or Prevalence (%)Age145438.6±10.6 21--3036326.5±2.8 (25.0%) 31--4050835.3±3.0 (34.9%) 41--5038944.7±2.7 (26.8%) 51--6517156.2±4.3 (11.8%) \>652370.4±3.5 (1.6%)Level of education Uneducated1147.8 Primary education16811.6 Middle school education76852.8 ≥University education40427.8Smoking Yes -- At least 3 times a week312.1 Yes -- Less than 3 times a week80.6 No141597.3Drinking Yes -- At least 2 times a week473.2 Yes -- Less than 2 times a week23115.9 No117680.9Number of pregnancies ≤293364.2 \>252135.8Number of childbirths ≤2124085.3 \>221414.7HR-HPV infection Positive64044.0 Negative81456.0[^1]

The prevalence of HR-HPV among women with ASCUS was 44.0% (640/1454) ([Table 1](#T0001){ref-type="table"}). [Table 2](#T0002){ref-type="table"} contains data on the prevalence rates of the different HPV genotypes among the women with ASCUS. HPV52 was the most prevalent, having been detected in 199 women (13.7%), followed by HPV58 (99/1454, 6.8%), HPV16 (95/1454, 6.5%), HPV51 (79/1454, 5.4%), HPV39 (49/1454, 3.4%), and HPV18 (46/1454, 3.2%).Table 2Prevalence of Different HR-HPV Genotypes Among Women with ASCUS (N=1454)Triage Criteria Using HR-HPV Type ModelsPositive n (%)Negative (n, %)HR-HPV640 (44.0%)814 (56.0%) HPV1695 (6.5%)1359 (93.5%) HPV1846 (3.2%)1408 (96.8%) HPV3138 (2.6%)1416 (97.4%) HPV3336 (2.5%)1418 (97.5%) HPV3513 (0.9%)1441 (99.1%) HPV3949 (3.4%)1405 (96.6%) HPV4520 (1.4%)1434 (98.6%) HPV5179 (5.4%)1375 (94.6%) HPV52199 (13.7%)1255 (86.3%) HPV5645 (3.1%)1409 (96.9%) HPV5899 (6.8%)1355 (93.2%) HPV5940 (2.8%)1414 (97.2%) HPV6644 (3.0%)1410 (97.0%) HPV6845 (3.1%)1409 (96.9%)[^2]

The rate of HR-HPV infection increased with the severity of the pathological diagnosis. The prevalence of HR-HPV was 31.2% among ASCUS women with normal pathology and 100% among ASCUS women with CIN3 or cancer. Among the women with ASCUS and biopsy-confirmed CIN2, the prevalence rates of HR-HPV genotypes were as follows: HPV16, 38.6%; HPV18, 6.8%; HPV31, 13.6%; HPV52, 36.4%; HPV58, 20.5%; and the 9 other types, 13.6%. Among the women with histologically confirmed CIN3, the incidence rates of HR-HPV were 57.1% (HPV16), 11.4% (HPV18), 0% (HPV31), 8.6% (HPV33), 20.0% (HPV52), 14.3% (HPV58), and 14.4% (other 8 types) ([Table 3](#T0003){ref-type="table"}).Table 3Distribution of HR-HPV Types According to Histological Diagnosis in Women with ASCUS (N=1454)HR-HPV Type ModelsHistological DiagnosisNormal n=1128, n (%)CIN1 n=239, n (%)CIN2 n=44, n (%)CIN3 n=35, n (%)Cancer n=8, n (%)HR-HPV352 (31.2%)203 (84.9%)42 (95.5%)35 (100.0%)8 (100.0%) HPV1629 (2.6%)24 (10.0%)17 (38.6%)20 (57.1%)5 (62.5%) HPV1821 (1.9%)18 (7.5%)3 (6.8%)4 (11.4%)0 (0.0%) HPV3118 (1.6%)14 (5.9%)6 (13.6%)0 (0.0%)0 (0.0%) HPV3317 (1.5%)15 (6.3%)0 (0.0%)3 (8.6%)1 (12.5%) HPV359 (0.8%)3 (1.3%)0 (0.0%)1 (2.9%)0 (0.0%) HPV3932 (2.8%)15 (6.3%)2 (4.5%)0 (0.0%)0 (0.0%) HPV459 (0.8%)8 (3.3%)2 (4.5%)0 (0.0%)1 (12.5%) HPV5150 (4.4%)26 (10.9%)1 (2.3%)2 (5.7%)0 (0.0%) HPV52109 (9.7%)67 (28.0%)16 (36.4%)7 (20.0%)0 (0.0%) HPV5624 (2.1%)20 (8.4%)0 (0.0%)1 (2.9%)0 (0.0%) HPV5847 (4.2%)37 (15.5%)9 (20.5%)5 (14.3%)1 (12.5%) HPV5925 (2.2%)13 (5.4%)1 (2.3%)1 (2.9%)0 (0.0%) HPV6628 (2.5%)16 (6.7%)0 (0.0%)0 (0.0%)0 (0.0%) HPV6832 (2.8%)13 (5.4%)0 (0.0%)0 (0.0%)0 (0.0%)[^3]

[Table 4](#T0004){ref-type="table"} shows the distribution of different HR-HPV genotype models according to the histological diagnosis of CIN2+ in women with ASCUS. The prevalence rate of HR-HPV increased as more HPV genotypes were combined. The combination of HPV16/18/31/33/58/52 was able to identify 93.1% (p \<0.001) of women whose cytology was ASCUS but histologically proven CIN2+, similar to the HR-HPV model (97.7%). However, based on HPV16/18 model, the rate was only 55.2%.Table 4Distribution of Different HR-HPV Genotype Models According to the Histological Diagnosis of CIN2+ in Women with ASCUS (N=1454)HR-HPV Genotype ModelsHistological Diagnosis*P*-valueNormal/CIN1 N=1367, n (%)CIN2+ N=87, n (%)HR-HPV555 (40.6%)85 (97.7%)\<0.001 HPV1653 (3.9%)42 (48.3%)\<0.001 HPV1839 (2.9%)7 (8.0%)0.018 HPV3132 (2.3%)6 (6.9%)0.025 HPV3332 (2.3%)4 (4.6%)0.338 HPV3512 (0.9%)1 (1.1%)0.794 HPV3947 (3.4%)2 (2.3%)0.791 HPV4517 (1.2%)3 (3.4%)0.216 HPV5176 (5.6%)3 (3.4%)0.550 HPV52176 (12.9%)23 (26.4%)\<0.001 HPV5644 (3.2%)1 (1.1%)0.446 HPV5884 (6.1%)15 (17.2%)\<0.001 HPV5938 (2.8%)2 (2.3%)0.790 HPV6644 (3.2%)0 (0.0%)0.169 HPV6845 (3.3%)0 (0.0%)0.162HPV16/18^a^90 (6.6%)48 (55.2%)\<0.001HPV16/18/58^b^167 (12.2%)63 (72.4%)\<0.001HPV16/18/52/58^c^326 (23.8%)77 (88.5%)\<0.001HPV16/18/31/52/58^d^348 (25.5%)80 (92.0%)\<0.001HPV16/18/31/33/58/52^e^369 (27.0%)81 (93.1%)\<0.001[^4][^5]

We analyzed the factors that may predict CIN2+ in women with ASCUS, as shown in [Table 5](#T0005){ref-type="table"}. HR-HPV-positive cases were associated with a 14.24 (95% CI: 7.42--27.34, p\<0.001) times greater probability of histological CIN2+ after adjustment for age. The risk was highest among women with HPV16 infection (OR: 37.38, 95% CI: 20.58--67.88, p\<0.001). HPV18 (OR: 4.62, 95% CI: 1.63--13.11, p=0.004), HPV31 (OR: 3.39, 95% CI: 1.07--10.70, p=0.038), HPV33 (OR: 2.22, 95% CI: 1.46--8.11, p=0.043), HPV52 (OR: 4.49, 95% CI: 2.42--8.31, p\<0.001) and HPV58 (OR: 6.97, 95% CI: 3.35--14.48, p\<0.001) were also associated with a higher risk of histological CIN2+, whereas HPV35, HPV39, HPV45, HPV51, HPV56, HPV59, HPV66, and HPV68 did not have a significant effect on the risk. We also estimated the risk of CIN2+ according to different HPV genotype models among women with ASCUS ([Table 5](#T0005){ref-type="table"}). The estimated ORs of CIN2+ were 8.89 (95% CI: 1.21--65.15, p=0.032) for the HPV16/18 model, 10.13 (95% CI: 3.90--26.35, p\<0.001) for the HPV16/18/58 model, 6.02 (95% CI: 2.99--12.13, p\<0.001) for the HPV16/18/52/58 model, 7.58 (95% CI: 3.88--14.79, p\<0.001) for the HPV16/18/31/52/58/model, and 9.91 (95% CI: 5.22--18.81, p\<0.001) for the HPV16/18/31/33/52/58 model.Table 5Factors Predicting CIN2+ in Women with ASCUSHR-HPV TypesNo. of Women (N=1454)OR (95% CI)OR~adjust~ (95% CI)^a^P-valueAge 21--303631 (R)1 (R) 31--405081.20 (0.66--2.19)1.68 (0.82--3.45)0.159 41--503891.60 (0.88--2.93)1.95 (0.95--4.04)0.071 51--651710.82 (0.34--2.00)1.29 (0.47--3.57)0.620 \>65231.83 (0.40--8.40)2.11 (0.22--19.79)0.514HR-HPV Negative8141 (R)1 (R) Positive64062.18 (15.24--253.74)14.24 (7.42--27.34)\<0.001HPV16 Negative13591 (R)1 (R) Positive9523.14 (14.00--38.24)37.38 (20.58--67.88)\<0.001HPV18 Negative14081 (R)1 (R) Positive462.98 (1.29--6.87)4.62 (1.63--13.11)0.004HPV31 Negative14161 (R)1 (R) Positive383.09 (1.26--7.60)3.39 (1.07--10.70)0.038HPV33 Negative14181 (R)1 (R) Positive362.01 (0.70--5.82)2.22 (1.46--8.11)0.043HPV35 Negative14411 (R)1 (R) Positive131.31 (0.17--10.22)2.17 (0.25--18.55)0.479HPV39 Negative14051 (R)1 (R) Positive490.66 (0.16--2.77)1.21 (0.25--5.86)0.815HPV45 Negative14341 (R)1 (R) Positive202.84 (0.82--9.87)2.60 (0.60--11.23)0.200HPV51 Negative13751 (R)1 (R) Positive790.61 (0.19--1.96)0.75 (0.18--3.06)0.689HPV52 Negative12551 (R)1 (R) Positive1992.43 (1.47--4.02)4.49 (2.42--8.31)\<0.001HPV56 Negative14091 (R)1 (R) Positive450.35 (0.05--2.57)0.29 (0.02--3.63)0.335HPV58 Negative21991 (R)1 (R) Positive2013.18 (1.75--5.79)6.97 (3.35--14.48)\<0.001HPV59 Negative14141 (R)1 (R) Positive400.82 (0.20--3.47)0.90 (0.19--4.32)0.895HPV66 Negative14101 (R)1 (R) Positive44///HPV68 Negative14091 (R)1 (R) Positive45///HPV16/18 model^b^ Negative13161 (R)1 (R) Positive13817.46 (10.88--28.04)8.89 (1.21--65.15)0.032HPV16/18/58 model^c^ Negative12241 (R)1 (R) Positive23018.86 (11.47--31.01)10.13 (3.90--26.35)\<0.001HPV16/18/52/58 model^d^ Negative10511 (R)1 (R) Positive40324.59 (12.58--48.07)6.02 (2.99--12.13)\<0.001HPV16/18/31/52/58 model^e^ Negative10261 (R)1 (R) Positive42833.47 (15.31--73.15)7.58 (3.88--14.79)\<0.001HPV16/18/31/33/52/58 model^f^ Negative10041 (R)1 (R) Positive45036.51 (15.80--84.39)9.91 (5.22--18.81)\<0.001[^6][^7]

The study endpoint was histological detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) at any of the follow-up visits. The sensitivity and NPVs of the HR-HPV genotype model increased, followed by those of the HPV16/18, HPV16/18/58, HPV16/18/52/58, HPV16/18/31/52/58, HPV16/18/31/33/52/58 and HR-HPV models. However, as the number of HPV genotype combinations increased, the specificity, PPV, PLR and NLR decreased ([Table 6](#T0006){ref-type="table"}). The sensitivity, specificity, PPV, NPV, PLR and NLR for detecting CIN2+ based on the HR-HPV model were 97.7% (94.6--99.9), 59.4% (56.8--62.0), 13.3% (10.7--15.9), 99.8% (99.4--100.0), 2.6 (2.2--2.6) and 0.04 (0.01--0.15), respectively. The sensitivity, NPV and NLR of the HPV16/18/31/33/52/58 model (sensitivity: 93.1% (87.8--98.4); NPV: 99.4% (98.9--99.9); NLR: 0.06 (0.03--0.18)) were similar to those of the HR-HPV model for identifying CIN2+ among women with ASCUS, but the specificity (73.0% (70.7--75.4)) and PPV (73.0% (70.7--75.4)) of the HPV16/18/31/33/52/58 model were higher than those of the HR-HPV model. In addition, the referral rate for the HPV16/18/31/33/52/58 model (30.9%) was lower than that for the HR-HPV model (44.0%) ([Table 6](#T0006){ref-type="table"}).Table 6The Effect of Different HR-HPV Genotype Models in Triaging Women with ASCUS. (N=1454)ModelsHR-HPV Model^a^HPV16/18 Model^b^HPV16/18/58 Model^c^HPV16/18/52/58 Model^d^HPV16/18/31/52/58 Model^e^HPV16/18/31/33/52/58 Model^f^Sensitivity% (95% CI)97.7 (94.6--99.9)55.2 (44.7--65.6)72.4 (63.0--81.8)88.5 (81.8--95.3)92.0 (86.2--97.7)93.1 (87.8--98.4)Specificity% (95% CI)59.4 (56.8--62.0)93.4 (92.1--94.7)87.8 (86.0--89.5)76.2 (73.9--78.4)74.5 (72.2--76.9)73.0 (70.7--75.4)PPV% (95% CI)13.3 (10.7--15.9)34.8 (26.8--42.7)27.4 (21.6--33.2)19.1 (15.3--22.9)18.7 (15.0--22.4)18.0 (14.5--21.5)NPV% (95% CI)99.8 (99.4--100.0)97.0 (92.1--98.0)98.0 (97.3--98.8)99.0 (98.5--99.6)99.3 (98.8--99.8)99.4 (98.9--99.9)PLR (95% CI)2.6 (2.2--2.6)8.9 (6.4--11.0)6.3 (4.9--7.2)3.9 (3.3--4.2)3.8 (3.2--4.0)3.7 (3.1--3.8)NLR (95% CI)0.04 (0.01--0.15)0.48 (0.38--0.61)0.31 (0.22--0.44)0.15 (0.08--0.27)0.11 (0.05--0.22)0.06 (0.03--0.18)Referral rate^g^% (n/N)44.0 (640/1454)9.5 (138/1454)15.8 (230/1454)27.7 (403/1454)29.4 (428/1454)30.9 (450/1454)[^8][^9]

Discussion {#S0004}
==========

ASCUS is the most frequent abnormal finding by cytology during cervical screening and can indicate either an active benign lesion or potential malignancy. Histological results may vary widely. Thus, a method to determine the appropriate clinical management strategy for women with ASCUS is needed. In recent years, HR-HPV DNA testing has been included in cervical screening programs, which can both be used to triage ASCUS patients[@CIT0019],[@CIT0020] and be a part of screening combined with TCT. Different HR-HPV genotypes are associated with different levels of risk for the progression of CIN to invasive cancer. The effectiveness of type-specific HR-HPV types in triaging ASCUS cases may vary by the specific combination of different HPV genotypes. Therefore, it is meaningful to identify the specific HR-HPV genotype model with higher sensitivity and specificity and lower referral rates to triage women with ASCUS.

Previous studies of the relevance of HR-HPV in the triage of ASCUS patients have mainly focused on HPV16 and HPV18. Data on HR-HPV types other than HPV16 and HPV18 are rare and inconsistent. Lin et al[@CIT0021] evaluated the role of HPV16/18 and other HR-HPV types in ASCUS and LSIL triage. A study conducted by Jiang et al[@CIT0022] analyzed the performance of 10 types of HR-HPV in the triage of ASCUS patients aged 25 to 36 years. Our study discusses the triage efficiency of different HR-HPV genotype models (HR-HPV, HPV16/18, HPV16/18/58, HPV16/18/52/58, HPV16/18/31/52/58, HPV16/18/31/33/52/58) for ASCUS patients, from a Chinese population, whose biopsies proved CIN2+. We found that the HPV16/18/58/52/31/33 model has a relatively high sensitivity, specificity, PPV, and NPV but a lower referral rate than other HR-HPV genotype models.

According to prior studies, the rate of ASCUS findings by cervical cytology ranges from 3% to 10%.[@CIT0023]--[@CIT0025] In accordance with these results, our research showed that ASCUS accounted for 4.9% of all cytology results. However, the prevalence of HR-HPV among women with ASCUS was quite inconsistent in different studies. Although one study reported that the prevalence rate of HR-HPV among women with ASCUS was 55.6%,[@CIT0026] another study reported a prevalence rate of 18%.[@CIT0027] In our study, we found that the prevalence rate of HR-HPV among ASCUS patients was 44%. Moreover, among ASCUS patients whose biopsies proved CIN2+, the infection rates of HPV16, HPV18, HPV31, HPV33, HPV52 and HPV58 were 48.3%, 8.0%, 6.9%, 4.6%, 26.4% and 17.2%, respectively. Our study also showed no HPV31 infection in ASCUS women with CIN3 and cervical cancer, which may be due to the small number of women we included. Previous studies showed that the risk of developing CIN3+ in HPV31-infected women was similar to that in HPV18-infected women,[@CIT0028] and even higher than that in HPV18-infected women.[@CIT0029] These findings suggest a higher possibility of progression to high-grade CIN in ASCUS patients who are infected with HPV16, HPV18, HPV31, HPV33, HPV52 or HPV58, which implies the significance of specific HPV genotype detection.

A meta-analysis[@CIT0002] compared the accuracy of the HR-HPV test with repeated cytology for potential CIN2+ or CIN3+ in ASCUS patients. The results indicated that the HR-HPV test is more sensitive than repeated cytology in the triage of ASCUS patients, but there is no significant difference in specificity. Our study shows that the sensitivity of HR-HPV to detect CIN2+ among ASCUS patients is 97.7% but that the specificity is only 59.4%. Therefore, triaging ASCUS patients with the recommended HR-HPV test will drive the evolution of referral rates and increase unnecessary costs and burden to patients. HPV16, HPV18, HPV31, HPV33, HPV52 and HPV58 are the most common genotypes in rural China, accounting for 88% of all infections, and infection with HPV16, HPV18, HPV31, HPV33, HPV52 and HPV58 among ASCUS patients is a higher risk factor for progressing to CIN2+[@CIT0030] This is consistent with our study results. Our data indicate that HPV16, HPV18, HPV31, HPV33, HPV52 and HPV58 are the most prevalent types among ASCUS patients with a histological diagnosis of CIN2+. Therefore, the risk of different HPV genotypes associated with CIN2+ among ASCUS patients was estimated.

We found that HR-HPV positivity was associated with a higher odds of CIN2+ histology. In the analysis of different HR-HPV genotypes, the risk of CIN2+ was highest among women with HPV16 infections. HPV18, HPV31, HPV33, HPV52 and HPV58 were also associated with the risk of histologically proven CIN2+, whereas HPV35, HPV39, HPV45, HPV51, HPV56, HPV59, HPV66, and HPV68 did not have a significant effect on the risk. An increased risk for CIN2+ was observed when the model combined more genotypes. The estimated OR of HPV16/18/31/33/52/58 was 9.91 according to our research.

We also calculated the sensitivity, specificity, PPV, and NPV of each HPV genotype combination, including HPV16/18, HPV16/18/58, HPV16/18/52/58, HPV16/18/31/52/58, HPV16/18/31/33/52/58 and HR-HPV, to identify potential CIN2+ populations among ASCUS patients. Similar to previous results,[@CIT0031] HPV16/18 was much more specific than the HPV16/18/31/33/52/58 combination (93.4% versus 73.0%) but lost sensitivity (55.2% versus 93.1%), which implies a higher possibility of misdiagnosis. However, we found that the sensitivity of HPV16/18/31/33/52/58 to identify CIN2+ in ASCUS cases was higher than that of HPV16/18/31/52/58, HPV16/18/52/58, or HPV16/18/58 (93.1% versus 92.0%, 93.1% versus 88.5%, 93.1% versus 72.4, respectively) and that the specificity of HPV16/18/31/33/52/58 was higher than that of HR-HPV (73.0% versus 59.4%). Moreover, according to the current guidelines for cervical cancer screening, HR-HPV-positive ASCUS patients are referred for colposcopy, and the referral rate of HPV16/18/31/33/52/58 was significantly lower than recommended for HR-HPV (30.9% versus 44.0%), which can effectively reduce the high burden of colposcopy referrals. Therefore, it is reasonable to believe that the HPV16/18/31/33/52/58 genotype model is an alternative triage strategy to identify CIN2+ among ASCUS patients in China.

The potential limitation of our study is that there may be overtreatment because we performed colposcopy and biopsy in all eligible ASCUS women included in the study. Although the purpose is to clarify their cervical lesions, most ASCUS women have not progressed to CIN2+ lesions. A second potential limitation is that our research was conducted in a single region, and we did not perform verification in other regions; thus, the results may not be generalizable to other places.

Conclusion {#S0005}
==========

This study evaluated the effectiveness of type-specific HR-HPV models in the triage of ASCUS patients in the large-scale population to date. Due to its high sensitivity, specificity, and minimal number of HR-HPV genotypes, we suggest the HPV16/18/31/33/52/58 genotype model as an alternative strategy for the triage of ASCUS patients. Developing specific HPV genotyping assays could significantly increase the cost-effectiveness of screening. To validate our results, further work is needed to evaluate our novel HPV genotype model in external populations.
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[^1]: **Abbreviation:** HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68.

[^2]: **Abbreviations:** HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68. ASCUS, atypical squamous cells of undetermined significance.

[^3]: **Abbreviations:** ASCUS, atypical squamous cells of undetermined significance; HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68; CIN, cervical intraepithelial neoplasia.

[^4]: **Notes:** ^a^Women with HPV16 and/or HPV18 infection. ^b^All women with positivity for HPV16, HPV18, or HPV58. ^c^All women with positivity for HPV16, HPV18, HPV52 or HPV58. ^d^All women with positivity for HPV16, HPV18, HPV31, HPV52 or HPV58. ^e^All women with any positivity for HPV16, HPV18, HPV31, HPV33, HPV52 or HPV58.

[^5]: **Abbreviations:** HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68; CIN, cervical intraepithelial neoplasia; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; ASCUS, atypical squamous cells of undetermined significance.

[^6]: **Notes:** ^a^OR values were adjusted for age, education level, smoking, drinking, number of pregnancies, and number of childbirths. ^b^Women with HPV16 and/or HPV18 infection directly referred for colposcopy and biopsy. ^c^All women with positivity for HPV16, HPV18, or HPV58 were directly referred for colposcopy and biopsy. ^d^All women with positivity for HPV16, HPV18, HPV52 or HPV58 were directly referred for colposcopy and biopsy. ^e^All women with positivity for HPV16, HPV18, HPV31, HPV52 or HPV58 were directly referred for colposcopy and biopsy. ^f^All women with positivity for HPV16, HPV18, HPV31, HPV33, HPV52 or HPV58 were directly referred for colposcopy and biopsy.

[^7]: **Abbreviations:** OR, odds ratio; ASCUS, atypical squamous cells of undetermined significance; HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68; R, reference.

[^8]: **Notes:** ^a^All women with positivity for HPV16, HPV18, HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66 or HPV68 were directly referred for colposcopy and biopsy. ^b^Women with HPV16 and/or HPV18 infection directly referred to colposcopy and biopsy. ^c^All women with positivity for HPV16, HPV18, or HPV58 were directly referred for colposcopy and biopsy. ^d^All women with positivity for HPV16, HPV18, HPV52 or HPV58 were directly referred for colposcopy and biopsy. ^e^All women with positivity for HPV16, HPV18, HPV31, HPV52 or HPV58 were directly referred for colposcopy and biopsy. ^f^All women with any positivity for HPV16, HPV18, HPV31, HPV33, HPV52 or HPV58 were directly referred for colposcopy and biopsy. ^g^The rate of referral for colposcopy among ASCUS women.

[^9]: **Abbreviations:** HR-HPV, high-risk human papillomavirus, including types HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, −66, −68; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio.
